Top Markets
Coin of the day
Kolon TissueGene, Inc. Kolon TissueGene, Inc.

Kolon TissueGene, Inc.

950160
Rank in Stocks #9085
Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the... Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the advancement of clinical-stage cell-based treatments for osteoarthritis. Its flagship offering is TG-C, a proprietary platform technology that integrates allogeneic primary cells with genetically engineered counterparts. Established by Kwan H. Lee on June 9, 1999, the enterprise maintains its corporate headquarters in Rockville, Maryland.
Share Price
$12.94
Last synced: 2026-08-28
Market Cap
$1.10B
Change (1 day)
-0.16%
Change (1 year)
-51.50%
Country
US
Trade Kolon TissueGene, Inc. (950160)

Category

Operating Margin for Kolon TissueGene, Inc. (950160)
Operating Margin as of 2026 TTM: 0.00%
According to Kolon TissueGene, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Kolon TissueGene, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
25.72% -
AU
-149.01% -
US
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.